Genzyme reports positive test of Gaucher disease drug
Genzyme reported positive results from a Phase 2 trial of a capsule intended to treat Gaucher disease.
The treatment, called eliglustat tartrate, showed “clinically meaningful” improvements in patients’ spleen size and hemoglobin and platelet levels. The Cambridge-based company said it is enrolling patients for Phase 3 trials.
Other treatments for Gaucher disease, including Genzyme’s own Cerezyme, are given to patients intravenously.
Source: Boston Herald
